Clofarabine/busulfan-based reduced intensity conditioning regimens provides very good survivals in acute myeloid leukemia patients in complete remission at transplant: a retrospective study on behalf of the SFGM-TC.
Fiche publication
Date publication
novembre 2018
Journal
Oncotarget
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BILGER Karin, Pr RUBIO Marie Thérèse
Tous les auteurs :
Bourgeois AL, Labopin M, Leclerc M, de Latour RP, Bourhis JH, Ceballos P, Orvain C, Wallet HL, Bilger K, Blaise D, Rubio MT, Guillaume T, Mohty M, Chevallier P,
Lien Pubmed
Résumé
Clofarabine has been proved to have higher anti-leukemic myeloid activity compared to fludarabine, a drug extensively used as part of reduced intensity conditioning (RIC) for allogeneic stem cell transplantation (allo-SCT).
Mots clés
acute myeloid leukemia, allogeneic stem cell transplantation, busulfan, clofarabine, reduced intensity conditioning regimen
Référence
Oncotarget. 2018 Nov 27;9(93):36603-36612